36 related articles for article (PubMed ID: 12572707)
1. The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients.
Yano Y; Hoshide S; Ishikawa J; Noguchi C; Tukui D; Takanori H; Tada M; Kanemaru Y; Yano A; Ishikawa S; Shimada K; Kario K
Am J Hypertens; 2007 May; 20(5):565-72. PubMed ID: 17485023
[TBL] [Abstract][Full Text] [Related]
2. Hypertension Management in Peripheral Artery Disease: A Mini Review.
Kharawala A; Nagraj S; Pargaonkar S; Seo J; Kokkinidis DG; Altin SE
Curr Hypertens Rev; 2024; 20(1):1-9. PubMed ID: 38083897
[TBL] [Abstract][Full Text] [Related]
3. Sympathetic Nervous System and Atherosclerosis.
Wang Y; Anesi J; Maier MC; Myers MA; Oqueli E; Sobey CG; Drummond GR; Denton KM
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685939
[TBL] [Abstract][Full Text] [Related]
4. First-line diuretics versus other classes of antihypertensive drugs for hypertension.
Reinhart M; Puil L; Salzwedel DM; Wright JM
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD008161. PubMed ID: 37439548
[TBL] [Abstract][Full Text] [Related]
5. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients.
Willeit P; Tschiderer L; Allara E; Reuber K; Seekircher L; Gao L; Liao X; Lonn E; Gerstein HC; Yusuf S; Brouwers FP; Asselbergs FW; van Gilst W; Anderssen SA; Grobbee DE; Kastelein JJP; Visseren FLJ; Ntaios G; Hatzitolios AI; Savopoulos C; Nieuwkerk PT; Stroes E; Walters M; Higgins P; Dawson J; Gresele P; Guglielmini G; Migliacci R; Ezhov M; Safarova M; Balakhonova T; Sato E; Amaha M; Nakamura T; Kapellas K; Jamieson LM; Skilton M; Blumenthal JA; Hinderliter A; Sherwood A; Smith PJ; van Agtmael MA; Reiss P; van Vonderen MGA; Kiechl S; Klingenschmid G; Sitzer M; Stehouwer CDA; Uthoff H; Zou ZY; Cunha AR; Neves MF; Witham MD; Park HW; Lee MS; Bae JH; Bernal E; Wachtell K; Kjeldsen SE; Olsen MH; Preiss D; Sattar N; Beishuizen E; Huisman MV; Espeland MA; Schmidt C; Agewall S; Ok E; Aşçi G; de Groot E; Grooteman MPC; Blankestijn PJ; Bots ML; Sweeting MJ; Thompson SG; Lorenz MW;
Circulation; 2020 Aug; 142(7):621-642. PubMed ID: 32546049
[TBL] [Abstract][Full Text] [Related]
6. Carotid Intima-media Thickness Measurements: Relations with Atherosclerosis, Risk of Cardiovascular Disease and Application in Randomized Controlled Trials.
Bots ML; Evans GW; Tegeler CH; Meijer R
Chin Med J (Engl); 2016 Jan; 129(2):215-26. PubMed ID: 26830994
[TBL] [Abstract][Full Text] [Related]
7. Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.
Wagstaff AJ
Drugs; 2006; 66(14):1881-901. PubMed ID: 17040120
[TBL] [Abstract][Full Text] [Related]
8. Doxazosin versus bendrofluazide: a comparison of the metabolic effects in British South Asians with hypertension.
Hobbs FR; Khan T; Collins B
Br J Gen Pract; 2005 Jun; 55(515):437-43. PubMed ID: 15970067
[TBL] [Abstract][Full Text] [Related]
9. How to study the role of hypertension in atherosclerosis. Lessons from MIDAS. Multicentre Isradipine Diuretic Atherosclerosis Study.
Hansson L
Blood Press Suppl; 1996; 4():16-9. PubMed ID: 8973777
[TBL] [Abstract][Full Text] [Related]
10. Sodium, large arteries, and diuretic compounds in hypertension.
Safar ME; Asmar R; Benetos A; Levy BI; London GM
Am J Med Sci; 1994 Feb; 307 Suppl 1():S3-8. PubMed ID: 8141162
[TBL] [Abstract][Full Text] [Related]
11. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands.
Hoogerbrugge N; de Groot E; de Heide LH; de Ridder MA; Birkenhägeri JC; Stijnen T; Jansen H
Neth J Med; 2002 Oct; 60(9):354-61. PubMed ID: 12572707
[TBL] [Abstract][Full Text] [Related]
12. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
Middeke M; Richter WO; Schwandt P; Holzgreve H
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
15. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
